一天14日对急性GVHD临床试验的终点
Nikolaos Spyrou1, Yu Akahoshi1, Steven Kowalyk1
1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Transplantation and cellular therapy
|February 6, 2024
概括
一个新的D14 MAGIC模型准确地预测了急性移植与宿主疾病 (GVHD) 患者的非复发性死亡率,为临床试验提供了比目前的D28标准反应更好的终点. 这种模型有助于在急性GVHD.早期治疗决策.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 目前的急性移植对宿主疾病 (GVHD) 临床试验使用28日的整体响应率 (ORR) 作为主要终点.
- 医生通常需要在28日之前调整免疫抑制.
- 非复发性死亡率 (NRM) 与28日ORR不一致相关.
研究的目的:
- 开发和验证急性GVHD非复发死亡率 (NRM) 的预测模型,允许更早的治疗干预.
- 评估14日新型模型的实用性,该模型将临床和生物标志物数据与标准28日终点相结合.
主要方法:
- 使用递归分区算法创建了西奈山模型,根据发病时和第14天的GVHD等级对患者进行分类.
- 结合血清ST2和REG3α度的MAGIC算法概率 (MAP) 与第14天的西奈山模型相结合.
- 分析了1144名全身急性GVHD患者的训练组 (n=764) 和验证组 (n=380).
主要成果:
- 第14天的西奈山模型根据发病时和第14天的整体GVHD等级预测了12个月的NRM.
- 结合的14日MAGIC模型将患者分为好NRM,中等NRM和差NRM组 (分别为8%,35%,76%NRM).
- 与28日标准响应模型相比,14日MAGIC模型表现出优异的性能 (AUC,灵敏度,预测值,净益).
结论:
- D14 MAGIC模型提供了一个更准确和及时的预测NRM在急性GVHD.
- 该模型可以协助治疗急性GVHD的决策.
- D14 MAGIC 模型显示了作为急性 GVHD 临床试验的改进终点的潜力.
关键词:
剧烈的GVHD是什么意思生物标志物 生物标志物分类树和回归树.竞争的风险 竞争的风险竞争的风险 竞争的风险复合材料是一种复合材料.决策曲线分析的方法终点 终点 终点免疫抑制是一种免疫抑制.机器学习是机器学习.没有复发的死亡率.代孕母亲是一个代孕母亲.时间依赖的AUC对治疗的反应反应.更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
7.1K
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...